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Women with germline mutations in BRCA1 have a
40% risk of developing ovarian cancer by age 70 [1]
and are also predisposed to cancers of the fallopian
tubes [2–4]. Given that ovulatory activity is a strong
risk factor for sporadic ovarian cancer [5], we hypoth-
esized that reduced BRCA1 expression might predis-
pose to gynecological cancers indirectly, by influenc-
ing ovarian granulosa cells. These cells secrete sex
steroids that control the ovulatory cycle and influ-
ence the growth of ovarian epithelial tumors [6, 7].
Granulosa cells also secrete mullerian inhibiting sub-
stance (MIS), a hormone that inhibits both the forma-
tion of female reproductive organs in male embryos
[8] and the proliferation of ovarian epithelial tumor
cells [9, 10]. We tested this hypothesis by using the
Cre-lox system to inactivate the Brca1 gene in mouse
ovarian granulosa cells. A truncated form of the Fsh
receptor promoter [11] served as the Cre driver. Here,
we show that indeed, inactivation of the Brca1 gene
in granulosa cells led to the development of cystic
tumors in the ovaries and uterine horns. These tu-
mors carried normal Brca1 alleles, supporting the
view that Brca1 may influence tumor development in-
directly, possibly through an effector secreted by
granulosa cells.
Results
Granulosa Cell Specificity of Truncated Fsh
Receptor Promoter
We verified the cell-type specificity of a truncated Fsh
receptor promoter form shown previously to direct ex-
pression exclusively in granulosa cells [11]. We crossed
a transgenic mouse expressing the Cre recombinase
under the control of this promoter fragment with the
ROSA26R Cre reporter mouse strain [12]. Examination
of the pelvic organs of mice carrying the Cre driver and*Correspondence: ldubeau@usc.edureporter showed β-galactosidase activity exclusively in
granulosa cells (Figure 1).
Consequences of Loss of Brca1 in Granulosa Cells
on Tumor Formation
Fshr-Cre transgenic mice were crossed with mice car-
rying a floxed Brca1 allele [13] to create a Brca1 homo-
zygous knockout restricted to granulosa cells. One
ovary was removed from each of 30 Brca1 flox/flox;
Fshr-Cre mice at 2 months of age. Histological exami-
nation revealed that these ovaries were morphologi-
cally normal (not shown). The mice were fertile and, at
least during the first 6 months of life, produced litters
of normal size.
Fifty-nine Brca1 flox/flox;Fshr-Cre mice, including the
30 mice that had a unilateral oophorectomy at two
months, were sacrificed between the ages of 12 and 20
months. Of these 59, 40 (68%) homozygous mutant
mice had grossly visible cysts attached to the ovary,
within the wall of the uterine horns, or on the external
surface of the uterine horns (Figure 2). The ovarian
cysts were occasionally bilateral (Figure 2). The uterine
cysts were usually multiple and most concentrated
near the ovaries. All cysts were lined by cuboidal to
columnar cells and were occasionally papillary (see Fig-
ure 3E, below). The cysts resembled human serous
cystadenomas, which are benign tumors composed of
the same cell type as ovarian serous carcinomas.
A solid tumor contiguous to a morphologically benign
cyst was observed in a single case. Although the com-
plexity and cellular atypia levels seen in the solid com-
ponent were compatible with a malignant process, the
malignant potential of this tumor remains unclear be-
cause it showed no evidence of either invasion of sur-
rounding structures or metastasis (Figure 2D). Renal
cysts were also observed in two mutant mice. No ab-
normality was seen in any of 36 age-matched littermate
controls lacking Cre recombinase.
Evidence for a Cell-Nonautonomous Mechanism
of Tumor Induction
Our studies with the R26R reporter mouse (Figure 1)
suggested that rearrangement of the Brca1 gene in re-
sponse to Fshr-Cre occurred primarily in ovarian granu-
losa cells, our intended target. That all tumors exhibited
an epithelial morphology suggested that they were not
derived from granulosa cells. Further support for this
possibility came from findings that the tumor cells (1)
expressed keratins (Figure 3), which are markers of epi-
thelial cells, and (2) did not express mullerian inhibiting
substance, a marker of granulosa cells (Figure 3). The
tumor cells also expressed estrogen (Figure 3) and pro-
gesterone (not shown) receptor proteins, further sup-
porting the view that they were functionally similar to
human ovarian epithelial tumors.
The conclusion that the tumors did not originate in
granulosa cells was also supported by the fact that
they were often localized in the uterine horns, which do
not contain granulosa cells. The possibility remained
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562Figure 1. Specificity of Fsh Receptor Pro-
moter for Granulosa Cells
Two transgenic mouse lines expressing Cre
recombinase under the control of a trun-
cated form [11] of the Fsh receptor promoter
(285 bp) were crossed with a ROSA26R Cre
reporter mouse. The pelvic organs were re-
moved at 8 weeks postnatal and examined
for the presence of lacZ under bright-field (A,
B, and D) or dark-field (E and F) microscopy.
Shown here are representative results from
one transgenic line.
(A) Ovaries with portion of adjacent uterine
horns; lacZ staining is restricted to the ova-
ries (arrows).
(B) Whole-mount section of one ovary show-
ing scattered foci of lacZ.
(C) Histological section of a mouse ovary
stained with an antibody against mullerian
inhibiting substance, a marker of granulosa
cells; this panel is meant to illustrate the normal histology of ovarian follicles for use as reference when examining panels (D)–(F); it shows
two ovarian follicles (short arrows), each with a central oocyte (long arrows) surrounded by immunopositive granulosa cells. Cells outside the
two ovarian follicles are ovarian stromal cells.
(D) Serial sections through an entire ovarian follicle morphologically similar to those shown in (C) and showing lacZ staining confined to the
granulosa cells.
(E) Whole-mount section through an entire ovary seen under dark-field microscopy showing the presence of lacZ in ovarian follicles; the area
within the rectangle, which shows a cross-section through the center of one follicle as well as small portions of adjacent follicles, is enlarged
in (F).that the Fshr-Cre transgene produced a Cre level that o
lwas sufficient to cause recombination of the floxed
Brca1 allele but was too low to cause recombination of i
lthe R26R allele. If this were the case, then the tumor
cells should carry the recombined form of the floxed B
WBrca1 allele. However, although the expected 530 bp
product from the unrearranged Brca1 allele could be A
famplified readily from all tissues examined with PCR
primers specific for this allele, the only tissues from w
cwhich the expected 640 bp product from the re-
arranged allele could be amplified were whole ovaries, i
the site of granulosa cells, as well as one of four ovarian
cysts that had been separated from the adjacent ova- g
hries with scissors under a dissecting microscope (Fig-
ure 4, bottom panel). The weak amplification product o
sobtained with primers specific for the rearranged allele
(pair e-d) in this ovarian cyst most likely reflects the t
cpresence of admixed ovarian stroma, either in the cyst
wall or in contaminating fragments of normal ovary. It e
lis highly unlikely that this allele played a role in tumor
development owing to its absence in most cystic tu- a
imors examined. A fifth ovarian cyst, subjected to laser
capture microdissection to ensure absence of admixed
Bgranulosa cells, did not contain the rearranged allele
either in the lining epithelium or in the cyst wall (Figure t
14, middle panel). We detected only the unrearraged al-
lele in the epithelial lining of two additional uterine cysts m





BOur results strongly support our hypothesis that inacti-
vation of the Brca1 gene in granulosa cells acts cell- c
cnonautonomously by altering the activity of an effector
that influences tumorigenesis in cells from which ovar- B
mian epithelial tumors originate. This conclusion is basedn the fact that inactivation of Brca1 in ovarian granu-
osa cells led to the formation of epithelial tumors carry-
ng normal Brca1 alleles. An earlier report showed simi-
arly that breast tumors resulting from inactivation of
rca1 in a subset of mammary cells (with MMTV-Cre or
ap-Cre) did not carry the mutant form of Brca1 [13].
lthough we did not examine breast tissue in Brca1
lox/flox;Fshr-cre mice, we note that ovulatory activity,
hich is controlled largely by the activity of granulosa
ells, is a well-established risk factor for breast cancer
n humans [14].
That mice lacking a functional Brca1 protein in their
ranulosa cells developed lesions involving the uterine
orns in addition to the ovaries is consistent with the
bservation that precancerous changes are frequently
een in the fallopian tubes of women who are asymp-
omatic carriers of BRCA1 mutations [2–4]. This is also
ompatible with L.D.’s earlier suggestion that ovarian
pithelial tumors do not originate from the mesothelial
ayer lining the ovarian surface, the site favored by most
uthors, but from mullerian duct derivatives surround-
ng the ovary or abutting this organ [15].
Most tumors that develop in individuals with germline
RCA1 mutations and show loss of heterozygosity at
he BRCA1 locus have retained the mutant allele [16–
8], suggesting that BRCA1 may act as a classical tu-
or suppressor. However, not all tumors that develop
n this group of patients carry losses of heterozygosity
t this locus [18], and there is little evidence for the
otion that the wild-type allele in these tumors is si-
enced by epigenetic mechanisms [19]. In addition, a
umber of observations suggest that total loss of
RCA1 activity does not promote, but interferes with
ellular growth. The small number of breast or ovarian
ancer cell lines so far isolated that lack a functional
RCA1 protein typically have long doubling times. Pri-
ary cultures derived from Brca1−/− mouse embryos
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563Figure 2. Examples of Ovarian and Uterine Lesions Observed in
Mutant Mice
Shown are gross photographs of ovarian (arrows in [A] and [B]) and
uterine (arrows in [E]) cysts and histological sections from ovarian
(C and D) and uterine (F–H) lesions. The ovarian tumor shown in (A)
was 80% cystic and 20% solid. Histological sections of both of
these components are shown in (C) and (D), respectively. A bilocu-
lar cyst on the external surface of a uterine horn is shown under
low and high magnification in panels (F) and (H), respectively. A
uterine horn containing multiple epithelial cysts (arrows) is shown
at low magnification in (G); ec denotes endometrial cavity. The
scale bars in (A), (B), and (E) represent 5 mm. The scale bars in (C),
(D), and (H) represent 40 m. The scale bars in (F) and (G) represent
1000 m. Stain: hematoxylin and eosin.do not proliferate unless the embryos also carry a p53
knockout. Given that cells from such embryos grow
only clonally, additional events must occur to ensure
their viability [20, 21]. Recent evidence suggests that
downregulation of BRCA1 results in growth arrest at the
G2 to M transition [22], a finding clearly inconsistent
with the view that Brca1 functions as a classical tumor
suppressor. That mutations in this ubiquitously ex-
pressed gene lead mainly to predisposition to breast
and ovarian cancer is also difficult to reconcile with
this view.It is possible that the Fshr promoter used in our
studies is expressed in cells other than granulosa cells
at levels undetectable with the R26R reporter mouse.
Thus, non-granulosa cells may control ovarian and
uterine tumorigenesis. However, we favor the hypothe-
sis that it is the granulosa cells that act at a distance
to control mullerian epithelial tumorigenesis via a
mechanism regulated by Brca1. At least in reproductive
organs, these cells appear to be the principal site of
Brca1 inactivation. The idea that a specific effector re-
leased by granulosa cells and regulated by Brca1 influ-
ences tumor predisposition in the mullerian tract is both
the simplest and biologically most attractive hypothe-
sis that follows from our data. Another possibility is that
an abnormal Brca1 expression might result in alter-
ations in the dynamics of the estrus cycle. An example
would be changes in the length of a specific phase of
this cycle. Such changes, in turn, might influence tu-
mor predisposition.
The finding that loss of Brca1 in mouse ovarian gran-
ulosa cells causes epithelial tumors in wild-type cells
of the ovary and uterus raises the prospect that re-
duced levels of functional BRCA1 protein in humans
carrying a germline BRCA1 mutation could lead to the
development of cancer by modulating the ability of
granulosa cells to act on distant target tissues. This
hypothesis has important implications for the clinical
management of individuals with a familial predisposi-
tion to ovarian tumors owing to germline BRCA1 muta-
tions. Knowing the identity of the endocrine or para-
crine factor(s) that mediates such actions at a distance
could provide a new way to identify individuals predis-
posed to ovarian cancer and could also form the basis
for novel strategies based on manipulations of the
levels of the factor(s) in question and aimed at prevent-
ing ovarian cancer in individuals with familial predispo-
sition to this disease.
Experimental Procedures
Immunohistochemical Analyses
The mouse monoclonal antibody against nonsquamous keratins
was purchased from Chemicon International (Temecula, CA, MAB
1611). The polyclonal goat antibody against mouse mullerian inhib-
iting substance was purchased from Santa Cruz Biotechnology
(Santa Cruz, CA, catalog number sc-6886). Goat polyclonal anti-
bodies against mouse estrogen receptor α and progesterone re-
ceptor proteins were purchased from Santa Cruz Biotechnology
(catalog numbers sc-542 and sc-2018, respectively). All primary
antibodies were diluted 1:200. For secondary antibodies, we used
either anti-mouse IgG purchased from Chemicon International (cat-
alog number AP124B) diluted 1:500 or anti-goat IgG purchased
from Santa Cruz Biotechnology and diluted 1:200. Antibody bind-
ing was detected with the ABC kit (Vector Laboratories, Burl-
ingame, CA).
Examination of Brca1 Rearrangement Status by PCR
Tissues of interest were either microdissected with a Pixcell II la-
ser-capture microdissection instrument (Arcturus Bioscience,
Mountain View, CA) or were sampled under a dissecting micro-
scope. All laser-capture microdissections were performed on tis-
sues fixed in ethanol only, embedded in paraffin, and either un-
stained or lightly stained with hematoxylin. Genomic DNA was
amplified by PCR with primers specific for either the unrearranged
(primers a-b) or rearranged (primers e-d) alleles. The sequences of
primers a and b were as published [13]. The sequence of primer e
(forward) was: 5#-GCAGTGAAGAGAACTTGTTCCT-3#. The se-
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564Figure 3. Immunohistochemical Character-
ization of Ovarian Tumors
(A)–(E) are various portions of the ovarian tu-
mor shown in Figure 2A. (E) shows a papil-
lary area of the cystic component. The sec-
tions were stained with a polyclonal antibody
against nonsquamous keratins (A and C) and
with monoclonal antibodies against either
mullerian inhibiting substance (B and D) or
the estrogen receptor protein (E). The cyto-
plasmic staining pattern seen in (E) is similar
to that seen in sections of normal endomet-
rium from wild-type mice (F). Secondary
mouse ovarian follicles stained with an anti-
body against mullerian inhibiting substance
were shown in Figure 1C. The scale bars re-
present 40 m in all panels except (E), in
which it is 100 m.quence of primer d (reverse) was: 5#-CTGCGAGCAGTCTTCAG
AAAG-3#. PCR cycling profiles were 30 s at 94°C, 60 s at 58°C, and
60 s at 72°C over 35 cycles.
Generation of Mice with Brca1 Knockout Targeted
to Granulosa Cells
A transgene composed of the Cre recombinase protein-coding se-
quence (1.1 kb) and a 900 bp SV40 fragment containing an un-
translated exon sequence and polyadenylation signal fused with a
truncated form [11] of the FSH receptor promoter (285 bp) was
used to produce transgenic mice. The initial parental mice were
from a cross between C57 and Black 6 strains. Six lines were ini-
tially created, two of which were crossed with R26R reporter mice
and found to be equally effective at driving Cre. One line was se-
lected randomly for breeding with a mouse carrying a floxed Brca1
allele described earlier [21]. The mouse genotypes were deter-
mined by amplifying tail DNA with primers specific for either the
floxed Brca1 allele or for Cre.
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